Blood cancers dominate CAR-T pipeline

Among the 13 CAR-T therapeutics that have received regulatory approval are Gilead’s Yescarta and Immuneel Therapeutics’ Qartemi.

Mar 21, 2025 - 06:00

Blood cancers dominate CAR-T pipeline

Among the 13 CAR-T therapeutics that have received regulatory approval are Gilead’s Yescarta and Immuneel Therapeutics’ Qartemi.

Read the original article

Tags:

Previous Article

Oxford BioTherapeutics and Roche link on antibody cancer treatments

Allogeneic cell therapies “poised for prime time” says expert

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

TTI-101 by Tvardi Therapeutics for Head And Neck Squamo...

Dec 4, 2023

Rankings

Oct 17, 2023

Managing temperature-sensitive injectable drugs in fill finish operations

Managing temperature-sensitive injectable drugs in fill...

Sep 26, 2024